Genomic analyses identify molecular subtypes of pancreatic cancer

By Peter Bailey, D. Chang, K. Nones, A. Johns, A. Patch, M. Gingras, David K. Miller, Angelika N. Christ, T. Bruxner, M. Quinn and 92 more. Nature, 2016

3,221 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/3f076549215f1666866c024936462912813a8a1b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Peter W. Laird
2. C. Théry
3. Hui Shen
4. S. Baylin
5. Eric S. Lander
6. Suresh Mathivanan
7. Timothy Triche
8. A. Llorente

In Oncology

1. Peter J. Campbell
2. S. Nik-Zainal
3. Michael R. Stratton
4. John N. Weinstein
5. Christopher Sander
6. Peter W. Laird
7. A. Richardson
8. H. Peinado

In Surgery

1. Hans Clevers
2. Jennifer J. Knox
3. Eric S. Lander

Citations in the corpus

• Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images (2018, background): “Molecular subtypes of ovarian, melanoma, and pancreatic cancer have been defined based on measures of immune infiltration (Cancer Genome Atlas Research Network, 2011; Cancer Genome Atlas Network, 2015; Bailey et al., 2016), and a number of other tumors show variation in immune gene expression by mol”
• Organoid profiling identifies common responders to chemotherapy in pancreatic cancer (2018, background): “119 Additional subtypes including Aberrantly Differentiated Endocrine Exocrine (ADEX) and Immunogenic 120 subtypes have been reported (11), but The Cancer Genome Atlas pancreas cancer project recently 121 demonstrated their association with tumors exhibiting low neoplastic cellularity, suggesting th”
• Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives (2021, background): “During the past several years, several subtypes of CAFs in pancreatic ductal adenocarcinoma (PDAC) have been identified through the application of transcriptome analyses, but none of these subtypes was given a specific definition [89, 90].”
• A novel community driven software for functional enrichment analysis of extracellular vesicles data (2017, background): “Advances in high-throughput techniques including next generation sequencing, RNA sequencing and proteomics have spurred enormous volume of data [1 – 3].”
• HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational-signatures (2017, background): “Previously, base-substitution signature 3 was shown to distinguish germline BRCA1 / BRCA2 -null cancers from sporadic cancers in a small subset of breast cancers 29,30 and was subsequently extended to pancreatic 32,33 , ovarian 34 and stomach 35 cancers.”
• Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. (2018, background): “%) of KRAS mutant pancreatic cancers (Bailey et al., 2016).”
• CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma (2016, positive): “Indeed, when we compare our mouse tumors with human tumors, we find that Cxcr2 deletion is associated with a switch away from the poorly prognostic squamous identity (Bailey et al., 2016).”